Arieh Ben-Yosef
Vorstandsvorsitzender bei Herd Moonitor Ltd.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Yosef Yeshayahu Wasserman | M | 65 | 6 Jahre | |
| Zvi Ioav Cabantchik | M | - |
The Hebrew University of Jerusalem
| 45 Jahre |
| Naor Eliyahu | M | 51 | 6 Jahre | |
| Avinoam Ben Nun | M | 73 | 6 Jahre | |
| Avraham Sarfaty | M | 48 | 7 Jahre | |
| Ziv Eisner | M | 49 | 7 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Udi Gilboa | M | 57 |
Alcobra Ltd.
 Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 6 Jahre |
| David Baker | M | 60 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 3 Jahre |
| Howard Rosen | M | 66 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 4 Jahre |
| Aharon Schwartz | M | 80 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 4 Jahre |
| Doron Pinhas Birger | M | 73 |
The Hebrew University of Jerusalem
| 7 Jahre |
| Clive P. Kabatznik | M | 66 |
The Hebrew University of Jerusalem
| 5 Jahre |
| Tomer Berkovitz | M | 44 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 4 Jahre |
| Marcelle Machluf | M | 61 | 9 Jahre | |
| Ronen Bezalel Melnik | M | 57 | 9 Jahre | |
| Ron Abraham Mayron | M | 60 | - | |
| Eyal Lewin | M | 58 | - | |
| Ram Belinkov | M | 68 |
The Hebrew University of Jerusalem
| 8 Jahre |
| Joao Siffert | M | 60 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
| Yuval Yanai | M | 71 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 1 Jahre |
| Eyal Desheh | M | 72 |
The Hebrew University of Jerusalem
| 7 Jahre |
| Gideon Schurr | M | 71 |
The Hebrew University of Jerusalem
| 6 Jahre |
| Daniel Geffken | M | 67 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 4 Jahre |
| Oded Shoseyov | M | 67 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Joseph Ginossar | M | 65 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Kamel Egbaria | M | 66 |
The Hebrew University of Jerusalem
| 5 Jahre |
| Eugene Kandel | M | - |
The Hebrew University of Jerusalem
| 10 Jahre |
| Shlomzion Shen | M | 54 | 1 Jahre | |
| Itamar Raz | M | - |
The Hebrew University of Jerusalem
| 3 Jahre |
| Shouky Oren | M | 66 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Noam Kfir | M | 53 | - | |
| Yaakov Stein | M | - |
The Hebrew University of Jerusalem
| 1 Jahre |
| Jonathan Rubin | M | 62 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 4 Jahre |
| Aharon Yaari | M | 72 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Moran Sherf Blau | F | 44 | - | |
| Jacob Harel | M | 69 | - | |
| Amit Segev | M | 69 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Michael Netz | M | 62 | - | |
| Daniel Tsiddon | M | - |
The Hebrew University of Jerusalem
| 3 Jahre |
| Yisrael Gewirtz | M | 47 | 5 Jahre | |
| Hagit Marchaim | M | - |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
| Meir Mishel Menachem | M | 58 | 1 Jahre | |
| Ronen Tsimerman | M | 54 | 2 Jahre | |
| Amalia Herszkowicz | F | - | 1 Jahre | |
| Boaz Laor | M | 72 |
The Hebrew University of Jerusalem
| 4 Jahre |
| David Ben Naim | M | 55 | 2 Jahre | |
| Orli Tori | M | - |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
| Moshe Manor | M | 67 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Shlomo Mor-Yosef | M | 73 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Aaron Hoffman | M | - |
The Hebrew University of Jerusalem
| 3 Jahre |
| Anat Bar-Gera | F | 66 |
The Hebrew University of Jerusalem
| 3 Jahre |
| Marius Nacht | M | - |
The Hebrew University of Jerusalem
| 4 Jahre |
| Jonathan Kollek | M | 65 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Asher Holzer | M | 74 |
The Hebrew University of Jerusalem
| 3 Jahre |
| David Heller | M | - |
The Hebrew University of Jerusalem
| 3 Jahre |
| Léo Apotheker | M | 69 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Harel Beit On | M | 64 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Amir Efrati | M | 50 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
| Livia Mahler | F | 65 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Roni Hefetz | M | - |
The Hebrew University of Jerusalem
| 3 Jahre |
| Zeev Zehavi | M | - |
The Hebrew University of Jerusalem
| 3 Jahre |
| Ofra Yamin | F | 61 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Dov Ofer | M | 70 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Oded S. Lieberman | M | 65 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Avraham Burg | M | 69 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Hezy Ram | M | - |
The Hebrew University of Jerusalem
| 2 Jahre |
| Moshe de Leon | M | - |
The Hebrew University of Jerusalem
| 4 Jahre |
| Tomer Kariv | M | 62 | 1 Jahre | |
| Assaf Shappir | M | - |
The Hebrew University of Jerusalem
| 14 Jahre |
| Shmuel Peleg | M | - |
The Hebrew University of Jerusalem
| - |
| Ra'anan Gefen | M | - |
The Hebrew University of Jerusalem
| 4 Jahre |
| Ran Nussbaum | M | 51 | 2 Jahre | |
| Tzippora Carmon | F | 71 |
The Hebrew University of Jerusalem
| 4 Jahre |
| David Zacut | M | 72 |
The Hebrew University of Jerusalem
| 3 Jahre |
| Adi Raviv | M | 69 |
The Hebrew University of Jerusalem
| 4 Jahre |
| Michal Sapir | F | 66 |
The Hebrew University of Jerusalem
| 11 Jahre |
| Eran Tzvi Ilan | M | 70 |
The Hebrew University of Jerusalem
| 3 Jahre |
| Yehuda Orbach | M | 71 |
The Hebrew University of Jerusalem
| 4 Jahre |
| George Yitzhak Klein | M | 71 |
The Hebrew University of Jerusalem
| 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Israel | 79 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Arieh Ben-Yosef
- Persönliches Netzwerk